Ulrichsen Sinna P, Mor Anil, Svensson Elisabeth, Larsen Finn B, Thomsen Reimar W
Department of Clinical Epidemiology, Faculty of Health, Aarhus University Hospital, Aarhus, Denmark.
Centre for Public Health and Quality Improvement, Central Denmark Region, Aarhus, Denmark.
PLoS One. 2014 Nov 4;9(11):e111849. doi: 10.1371/journal.pone.0111849. eCollection 2014.
To examine the lifestyle profile among persons with and without Type 2 diabetes mellitus (DM) and among users of different glucose-lowering drugs.
We used questionnaire data from a Danish health survey and identified presence of Type 2 DM and use of medications through medical databases. We calculated age- and gender-standardized prevalence ratios (PRs) of lifestyle factors according to Type 2 DM and different glucose-lowering drugs.
Of 21,637 survey participants aged 25-79 years, 680 (3%) had Type 2 DM (median age 63 years) with a median diabetes duration of 5 years. Participants with Type 2 DM had a substantially higher prevalence of obesity (36% vs. 13%, PR: 3.1, 95% confidence interval (CI): 2.8-3.6), yet more reported to eat a very healthy diet (25% vs. 21%, PR: 1.2, 95% CI: 1.0-1.4) and to exercise regularly (67% vs. 53%, PR: 1.3, 95% CI: 1.2-1.4). Also, fewer were current smokers or had high alcohol intake. When compared with metformin users, obesity was substantially less prevalent in users of sulfonylurea (PR: 0.5, 95% CI: 0.4-0-8), and insulin and analogues (PR: 0.4, 95% CI: 0.3-0.7). Tobacco smoking was more prevalent in sulfonylurea users (PR: 1.4, 95% CI: 0.9-2.1) compared with metformin users. We found no material differences in physical exercise, diet or alcohol intake according to type of glucose-lowering drug.
Type 2 DM patients are substantially more obese than other individuals, but otherwise report to have a healthier lifestyle. Metformin use is strongly associated with obesity, whereas sulfonylurea use tends to be associated with tobacco smoking.
研究2型糖尿病患者与非2型糖尿病患者以及不同降糖药物使用者的生活方式概况。
我们使用了丹麦健康调查的问卷数据,并通过医学数据库确定2型糖尿病的存在情况和药物使用情况。我们根据2型糖尿病和不同降糖药物计算了生活方式因素的年龄和性别标准化患病率比(PRs)。
在21637名年龄在25 - 79岁的调查参与者中,680人(3%)患有2型糖尿病(中位年龄63岁),糖尿病病程中位数为5年。2型糖尿病患者的肥胖患病率显著更高(36%对13%,PR:3.1,95%置信区间(CI):2.8 - 3.6),但更多人报告饮食非常健康(25%对21%,PR:1.2,95%CI:1.0 - 1.4)且经常锻炼(67%对53%,PR:1.3,95%CI:1.2 - 1.4)。此外,当前吸烟者或高酒精摄入量者较少。与二甲双胍使用者相比,磺脲类药物使用者(PR:0.5,95%CI:0.4 - 0.8)以及胰岛素和类似物使用者(PR:0.4,95%CI:0.3 - 0.7)的肥胖患病率显著更低。与二甲双胍使用者相比,磺脲类药物使用者的吸烟率更高(PR:1.4,95%CI:0.9 - 2.1)。我们发现根据降糖药物类型,体育锻炼、饮食或酒精摄入量没有实质性差异。
2型糖尿病患者比其他个体肥胖得多,但报告的生活方式更健康。使用二甲双胍与肥胖密切相关,而使用磺脲类药物往往与吸烟有关。